Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115349 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
A Phase 2 study, sponsored by Carelon Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00115349: Clinical Trial Phase 2 study, sponsored by Carelon Research.
NCT00115349 is a Phase 2 study that was terminated before completion, run by Carelon Research. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00115349, a Phase 2 study, was terminated before completion, sponsored by Carelon Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether left ventricular function improves more rapidly with deferoxamine (DFO) and deferiprone (L1) combination therapy than with DFO monotherapy in patients with thalassemia and decreased ejection fractions. Secondary aims include evaluating changes in myocardial iron burden using T2\* and estimating the relative incidence and severity of chelator-induced toxicity.
Primary Outcome
The primary outcome variable is change in left ventricular ejection fraction (blood ejected from the heart into the body) as measured by MRI from baseline to one year. The unit of primary outcome (left ventricular ejection fraction) is the percent of the blood in left ventricle.
Interventions
- DRUG Deferoxamine
- DRUG Deferiprone (L1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Why NCT00115349 stopped before completion
NCT00115349 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Deferoxamine is the first listed.
NCT00115349 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00115349 about?
NCT00115349 is a clinical study titled "Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases". The purpose of this study is to determine whether left ventricular function improves more rapidly with deferoxamine (DFO) and deferiprone (L1) combination therapy than with DFO monotherapy in patients with thalassemia and decreased ejection fractions. Secondary aims include evaluating changes in myo...
What is the current status of trial NCT00115349?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00115349?
The interventions under investigation include: Deferoxamine (DRUG), Deferiprone (L1) (DRUG).
Who is sponsoring clinical trial NCT00115349?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00115349's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia